natgillin/translations-raw huggingface dataset:
Device according to claim 9, characterized in that it comprises a means for determining the energy used for the breaking of the weakening zone (24). 
Uređaj sukladno bilo kojem od zahtjeva 1 do 9, naznačen time što sadrži sredstva za određivanje energije upotrebljene za lomljenje zone slabljenja (24).
Particularly preferably, at least one constituent of the hot substance drugs is selected from the group consisting of myristicin, elemicin, isoeugenol, B-asarone, safrole, gingerols, xanthorrhizol, capsaicinoids, preferably capsaicin, capsaicin derivatives, such as N-vanillyl-9E-octadecenamide, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, norcapsaicin and nomorcapsaicin, piperine, preferably trans-piperine, glucosinolates, preferably based on non-volatile mustard oils, particularly preferably based on p-hydroxybenzyl mustard oil, methylmercapto mustard oil or methylsulfonyl mustard oil, and compounds derived from these constituents. 
Naročito se preferira barem jedan sastojak nadražujućih droga izabranih iz skupine koja se sastoji iz miristicina, elemicina, izoeugenola, a-asarona, safrola, gingerolena, ksantorizola, kapsaicinoidena, prvenstveno kapsaicina, kapsaicin-derivata, kao N-vanilil-9E-oktadecenamida, dihidrokapsaicina, nordihidrokapsaicina, homokapsaicina, norkapsaicina, i nomorkapsaicina, piperina, prvenstveno trans-piperina, glukozinolata, prvenstveno na bazi nehlapivih ulja gorušice, osobito pogodno na bazi p-hidroksibenzilgorušičinog ulja, metilmerkaptogorušičinog ulja ili metilsulfonilgorušičinog ulja, i spojeva izvedenih od ovih sastojaka.
Cyclopentanone (10.0g, 118.9 mmol) was taken up in absolute ethanol (30 cm3) and sodium ethoxide (53 cm3, 21% in ethanol, 143 mmol) was added. 
Ciklopentanon (10.0 g, 118.9 mmol) je preuzet u apsolutni etanol (30 cm?) i dodan je natrij etoksid (53 cm, 21% etanol, 143 mmol).
A crystalline Form IA of Prasugrel hydrobromide according to formula I, 
Kristalni oblik IA prasugrel-hidrobromida u skladu s formulom I: 2 CD"
Total 2-layer tablet * Volatile component, does not remain in final product A pharmaceutical tablet comprising a first layer of telmisartan in a dissolving tablet matrix comprising a basic agent selected from alkali metal hydroxides, basic amino acids and meglumine, a water-soluble diluent and, optionally, other excipients and adjuvants and a second layer of amlodipine in a disintegrating or eroding tablet matrix. 
Farmaceutska tableta, naznačena time, da obuhvaća prvi sloj od telmisartana u rastapajućoj tabletnoj matrici koja sadrži osnovno sredstvo odabrano od sljedećih: hidroksidi alkalijskog metala, osnovne aminokiseline i meglumin, zatim sadrži razrjeđivač topiv u vodi i po potrebi ostale pomoćne tvari i dopunska sredstva, te obuhvaća drugi sloj od amlodipina u tabletnoj matrici koja se rastavlja, primjerice dezintegrira ili erodira.
Y represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and 
Y predstavlja vodikov atom ili alkilnu skupinu koja ima 1 do 6 ugljikovih atoma; i
the second fragment is a C . difficile toxin B repeating domain fragment; 
(ii) drugi fragment je fragment ponavljajuće domene toksina B iz bakterije C. difficile;
wherein when the current coding unit is predicted according to the intra mode, a maximum split level of a transformation unit with respect to the current coding unit predicted according to the intra mode is determined based on the maximum split information for the intra mode, wherein when the current coding unit is predicted according to the inter mode, a maximum split level of a transformation unit with respect to the current coding unit predicted according to an inter mode is determined based on the maximum split information for the inter mode, 
Postupak dekodiranja video zapisa prema zahtjevu 1, naznačen time da se informacije o maksimalnoj podjeli za jedinicu transformacije s unutarnjim načinom i informacije o maksimalnoj podjeli za jedinicu transformacije s inter načinom dobivaju kao parametri u odnosu na jednu razinu podataka između razina podataka koji obuhvaćaju niz slika, sliku, isječak, te podatkovnu jedinicu za kodiranje videa.
compressed rolls (1a, 1b, 1c, 1d, 2a, 2b, 2c, 2d) or mineral wool which are individually packaged within a plastic film or compressed stacks of mineral wool panels (22a, 22b, 22c, 22d, 22e, 22f, 22g, 22h) which are packed in a plastic film (3) to form a package of panels, wherein 
- - stlačene valjke (Ia, Ib, Ic, Id, 2a, 2b, 2c, 2d) mineralne vune koji su pojedinačno pakirani u plastičnoj foliji ili stlačene stogove ploča od mineralne vune (224, 22b, 22c, 22d, 22e, 22f, 22g, 22h) koji su pakirani u plastičnoj foliji (3) i čine paket ploča, pri čemu
Other suitable meglitinides include nateglinide (Novartis) or KAD1229 (PF/Kissei). 
Drugi pogodni meglitinidi obuhvaćaju nateglinid (Novartis) ili KAD 1229 (PF/Kisse1).
and R4, independently of one another, are a branched or straight C1- to C10-alkyl radical, C5- to C8-cycloalkyl radical, aryl radical, heteroaryl radical or H; 
i R4, međusobno nezavisni, su granati ili linearni C1- do C10-alkil radikal, C5- do C8-cikloalkil radikal, aril radikal, heteroaril radikal ili H;
wherein P1 is an amino protecting group, thereby forming the compound of formula II. 
-a-_> u čemu je P, amino zaštitna skupina, da na taj način nastane spoj formule II.
A siphon apparatus as claimed in claim 9, wherein the centre portion is hollow. 
Sifonski aparat prema patentnom zahtjevu 7, pri čemu je centralni dio šupalj.
removing free polyethylene glycol from the pegylated AvPAL variant by ultrafiltation/diafiltration; and 
uklanjanju slobodnog polietilen-glikola iz pegilirane varijante AvPAL ultrafiltriranjem/dijafiltriranjem; i
in case it is an antibody molecule composition it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line ATCC No. 
CRL-9096 (CHOdhfr-); – ima povećani prosječni ili maksimalan prinos, koji je najmanje 10% veći od prinosa pripravka s najmanje jednom molekulom proteina iz iste molekule proteina kada se eksprimira u staničnoj liniji ATCC No.
Brazing medium in the form of foil or a sheet 
Sredstvo za lemljenje u obliku folije ili lima
The process of claim 1, where the crystalline hydrochloride salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 
Spoj sukladno patentnom zahtjevu 1, naznačen time, da mu trag diferencijalne pretražne kalorimetrije u biti u skladu s onim koji je prikazan na SI.
An in vitro or ex vivo method for inducing and/or promoting skipping of at least exon 52 of the dystrophin pre-mRNA in an isolated cell of a patient, the method comprising providing said cell with an oligonucleotide as defined in any one of claims 1 to 4 or the vector of claim 5. 
In vitro metoda za induciranje ili promoviranje preskakanja eksona 45 pre-mRNA distrofina u izoliranoj stanici navedenog pacijenta, metoda obuhvaća opskrbljivanje navedene stanice besmislenim oligonukleotidom kako je definirano u bilo kojem od patentnih zahtjeva 1-14, vektor iz patentnog zahtjeva 15, ili farmaceutski sastav iz patentnog zahtjeva 16.
Shielding device to reduce the impact of electromagnetic radiation 
ZAŠTITNA NAPRAVA ZA SMANJENJE UTJECAJA ELEKTROMAGNETSKOG ZRAČENJA
inner decoding the L1 signaling data by a Low Density Parity Check, LDPC coding scheme and outer decoding the inner decoded L1 signaling data by a Bose-Chadhuri-Hocquenghem, BCH, coding scheme; 
Metoda iz patentnog zahtjeva 7, pri čemu metoda nadalje obuhvaća: unutarnje dekodiranje PLP podataka shemom kodiranja provjere pariteta niske gustoće; i vanjsko dekodiranje vanjsko dekodiranih PLP podataka pomoću sheme kodiranja Bose-Chadhuri-Hocquenghem, BHC.
An inhaler according to claim 6, wherein the piercing member comprises at least two discrete piercing heads operable to pierce a corresponding number of holes in a blister aligned with the blister piercing member. 
Inhalator prema zahtjevu 2 ili 3, gdje dio za bušenje (9,75) obuhvaća barem dvije zasebne glave za bušenje koje mogu probušiti odgovarajući broj rupica u blisteru koji je u ravnini s dijelom za bušenje blistera (9,75).
The composition or vaccine for use according to claim 3 or 4, wherein the animal is avian. 
Sastav, cjepivo ili vektor za uporabu prema bilo kojem od zahtjeva 1 do 9 ili 11 do 13, naznačeni time, da životinja je ptica.
The composition for the use according to claim 6 wherein the composition provides treatment for opioid dependence or pain relief over a period of at least 7 days and no more than 28 days. 
Supstanca za upotrebu prema patentnom zahtjevu 6 pri čemu ova supstanca osigurava terapiju kod ovisnosti o opijatima ili ublažavanje bolova tokom perioda od najmanje 7 dana a ne dužeg od 28 dana.
The method according to claim 2, wherein the duration, rotational speed and/or intensity of rotation of said mixing element in said first direction is the same as the duration, rotational speed and/or intensity of rotation of said mixing element in said second direction. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su trajanje, brzina vrtnje i/ili intenzitet vrtnje navedenog elementa za miješanje (60) u navedenom prvom smjeru isti kao trajanje, brzina vrtnje ifili intenzitet vrtnje navedenog elementa za miješanje (60) u navedenom drugom smjeru.
The pharmaceutical composition for use according to claim 12, wherein the cancer is cancer of the buccal cavity and pharynx, cancer of the digestive tract, cancer of the colon, rectum, and anus, cancer of the respiratory tract, breast cancer, cancer of the cervix uteri, vagina, and vulva, cancer of the uterine corpus and ovary, cancer of the male genital tract, cancer of the urinary tract, cancer of the bone and soft tissue, and Kaposi sarcoma, melanoma of the skin, eye melanoma, and non-melanoma eye cancer, cancer of the brain and central nervous system, cancer of the thyroid and other endocrine glands, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and myeloma, such as renal cancer, colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, gastric cancer, GIST or glioblastoma. 
Farmaceutski sastav za uporabu prema zahtjevu 12, pri čemu je karcinom karcinom usne šupljine 1 ždrijela, karcinom probavnog trakta, karcinom debelog crijeva, rektuma i anusa, karcinom respiratornog trakta, karcinom dojke, karcinom grlića maternice, vagine i vulve, karcinom tijela maternice 1 jajnika, karcinom muškog genitalnog trakta, karcinom urinarnog trakta, karcinom kostiju i mekog tkiva, Kaposijev sarkom, melanom kože, melanom oka, nemelanomski karcinom oka, karcinom mozga i središnjeg živčanog sustava, karcinom žlijezde štitnjače i drugih endokrinih žlijezda, Hodgkinov limfom, ne-Hodgkinov limfom, ili mijelom kao što su karcinom bubrega, kolorektalni karcinom, karcinom pluća, karcinom dojke, karcinom gušterače, karcinom prostate, karcinom želuca, gastrointestinalni stromalni tumor (GIST) ili glioblastom.
The rounding at the introduction end is designed in such a manner that the sampler can be introduced painlessly and easily by the user, unlike a flexible tube or sampling brushes or scrapers which are currently used to remove cells from the cervix for examination. 
Zaobljenje na onom kraju koji se uvodi izvedeno je na takav način, da napravu za uzimanje uzorka može bezbolno i lagano uvesti sama korisnica, za razliku od fleksibilnih cijevi ili četki ili strugalica za uzimanje uzorka kakvi se danas koriste za uzimanje stanica iz grlića maternice radi ispitivanja.
Ring A is unsubstituted or is substituted with ethyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.. 
Prsten A je nesupstituiran ili je supstituiran s etil; ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
Aspect 61. The apparatus according to aspect 60, wherein the adjustment device further comprises a reverse servo, and wherein a small volume of fluid in the reservoir is compressed with a higher force and the chamber creates a movement of a larger total volume with less force per unit of volume. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 6 i 8, naznačen time što uređaj za rukovanje ima reverzibilni servo (90), te što se mali volumen fluida u spremniku fluida pritišće većom silom, a komora tijela potiče kretanje većeg ukupnog volumena manjom silom po jedinici volumena.
The use of 3,11b- cis -dihydrotetrabenazine for the manufacture of a medicament for the prophylaxis or treatment of psychosis. A method for the prophylaxis or treatment of psychosis, the method comprising administering to the mammal a therapeutically effective amount of cis -dihydrotetrabenazine. 
* - Uporabu 3,11b-cis-dihidrotetrabenazin Izomera A za pripremu lijeka za (1) profilaksu ili liječenje psihoze; ili (ii) za profilaksu ili liječenje šizofrenije.
The process of any one of claims 1-4 wherein the carrier protein is selected from the group consisting of tetanus toxoid, fragment C of tetanus toxoid, diphtheria toxoid, CRM197, Pneumolysin, protein D, PhtD, PhtDE and N19. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što se proteinski nosač bira iz skupine koju čine tetanusni toksoid, fragment C tetanusnog toksoida, difterijski toksoid, CRM197, pneumolizin, protein D, PhtD, PhtDE i N19.
The method of claim 5, wherein FEC encoding L1 signaling data comprises: BCH encoding the L1 signaling data; 
Metoda iz patentnog zahtjeva 5, pri čemu koder prednjeg ispravljanja pogreške signalnog podatka LI obuhvaća: BCH kodiranje signalnog podatka razine 1;
A2A binding analysis: 
Analiza vezanja na A2, receptore:
<400> 190 A human monoclonal therapeutic anti ActRIIB antibody or functional protein comprising an antigen binding portion thereof, comprising a VH polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 99-112 and a VL polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 85-98, wherein said antibody or functional protein comprising an antigen binding portion thereof inhibits myostatin binding to ActRIIB. 
Humano monoklonsko terapeutsko protutijelo anti-ActRIIB ili funkcionalni protein koji obuhvaća njegov dio koji veže antigen, naznačen/o time, da obuhvaća jednu VH-polipeptidnu sekvencu koja ima najmanje 95% identiteta sekvence od barem jedne od SEQ ID NOs: 99-112, i jednu VL-polipeptidnu sekvencu koja ima najmanje 95% identiteta sekvence od barem jedne od SEQ ID NOs: 85-98, pri čemu navedeno protutijelo ili navedeni funkcionalni protein koji obuhvaća njegov dio koji veže antigen, inhibira vezanje miostatina na ActRIIB.
According to this third variant, the said formic or citric acid salt is preferentially a mono-, di- or tri-alkaline salt, and is more preferentially a salt of a cation of Group I or II of the Periodic Table of the Elements. 
Postupak prema zahtjevu 6, naznačen time da navedena sol mravlje ili limunske kiseline je mono-, di- ili trialkalna sol, te je poželjno sol kationa iz skupine I ili II periodne tablice elemenata.
The method of claim 1, wherein the antibody or fragment thereof comprises (a) a HCVR sequence of SEQ ID NO:20 or 116, and a LCVR sequence of SEQ ID NO:28 or 118, or (b) a HCVR/LCVR combination of SEQ ID NO:20/28 or 116/118. 
Primjena prema zahtjevu 8, naznačena time, što se antitijelo ili njegov fragment sastoji od (a) HCVR sekvence od SEQ ID NO: 20 ili 116 1 LCVR sekvence od SEQ ID NO:28 ili 118, ili (b) HCVR/LCVR kombinacije od SEQ ID NO: 20/28 ili 116/118.
and catechin polyphenols; for the preparation of oral formulations for the oral hygiene and for the treatment and prevention of disorders of the oral cavity of various origins. 
4) benzofenantridinskih alkaloida, b) spojcva benzofurana, to c) katekinskih polifenola, naznačena time da je za pripravu oralnih formulacija za oralnu higijenu te za tretman i prevenciju poremećaja usne šupljine raznog porijekla.
The wet material was refluxed in 300 ml of methanol for 30 min and then filtered through a hyflow bed. 
Vlažni materijal je doveden do refluksa u 300 ml metanola tijekom 30 minuta te zatim filtriran kroz hyflow podlogu.
Further characteristic of the monohydrate form were the signals with chemical shift values of 159.0, and 150.9, and 40.7 ppm. 
Nadalje su karakteristike monohidratnog oblika signali sa kemijskim pomakom od 159.0, i 150.9, i 40.7
is carboxylic, phosphonic, or phosphoric; is arylene; and 
je karboksilna, fosfonska, ili fosforna, u njezinom obliku soli ili obliku kiseline; je arilen;
The method of claim 1, wherein the first waste stream is heated to a temperature of at least 200 °C. 
povećanje temperature kombiniranog prvog toka otpada i sorbenta do temperature od najmanje 290 °C;
upon storage of the composition at 30 °C and 65% RH for a period of 6 months, the EPA has a second peroxide value not greater than 12 Meq/kg, not greater than 10 Meq/kg or not greater than 6 Meq/kg. 
Farmaceutski pripravak prema zahtjevu 1 naznačen time da nakon skladištenja pripravka na 30 "C i 65% RH kroz period od 6 mjeseci, EPA ima drugu peroksidnu vrijednost ne veću od 12 Meqg/kg, ili ne veću od 10 Meq/kg, ili ne veću od 6 Meq/kg.
The product was crystallized as an oxalate salt by dissolution in acetone and addition of one equivalent of oxalic acid. 
Proizvod je kristaliziran kao oksalatna sol rastapanjem u acetonu uz dodatak jednog ekvivalenta oksalne kiseline.
Additional specific embodiments of the invention include: 
Datum podnošenja europske prijave patenta:
—C(O)O—C1-6-alkyl, wherein the C1-6-alkyl is unsubstituted or substituted by 1 to 5 substituents individually selected from the group consisting of OH, halogen, cyano and C1-6-alkoxy; vi) cycloalkyl, unsubstituted or substituted by 1 to 5 substituents individually selected from the group consisting of OH, halogen, cyano, C1-6-alkyl and C1-6-alkoxy; 
(v) -C(O)O-C.s-alkil, gdje je C,s-alkil nesupstituiran ili supstituiran s 1 do 5 supstituenata pojedinačno odabranih iz skupine koju čine: OH, halogen, cijano i Ci.4-alkoksi, (vi) cikloalkil, nesupstituiran ili supstituiran s 1 do 5 supstituenata pojedinačno odabranih iz skupine koju čine: OH, halogen, cijano, C,.g-alkil and C;.4-alkoksi;
Thus, in some embodiments, it is advantageous to stabilize the native filler ingredient in order to obtain a metastable phase that will not undergo more or less spontaneous, i.e. premature, transformation upon storage of the composite material. Stabilization of the metastable phase can, e.g., be achieved by doping, by surface modification of the filler particles, etc. as will be explained in the following. Doping 
Stoga je u nekim cjelinama poželjno stabilizirati prirodni sastojak za punjenje da se dobije metastabilna faza u kojoj se punilo neće više ili manje spontano, t.j. prerano, transformirati nakon skladištenja kompozitnog materijala, kao što će biti objašnjeno, stabilizacija metastabilne faze može npr. biti postignuta dopiranjem, modifikacijom površine čestica za punjenje itd. Dopiranje
The composition for use according to any one of claims 6 to 9, wherein the gelatin is fish gelatin. 
Pripravak naznačen time da je za uporabu prema zahtjevu 8 u postupku koji sadrži:
the term "heterocycloalkyl" refers to a monovalent non-aromatic group with a carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of one or more non-aromatic ring structures wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, wherein the heterocycloalkyl group consists of no atoms other than carbon, hydrogen, nitrogen, oxygen and sulfur, wherein, if more than one ring is present, the rings may be fused or unfused, wherein, the one or more alkyl groups may be attached to the ring or ring system, if permitted by the carbon number limitation, and wherein one or more double bonds may be present in the ring or ring system, provided that the resulting group remains non-aromatic; 
izraz "heterocikloalkil" odnosi se na jednovalentnu ne-aromatsku skupinu s ugljikovim atomom ili dušikovim atomom kao točkom spajanja, navedeni ugljikov atom ili dušikov atom tvore dio jedne ili više ne-aromatskih prstenastih struktura pri čemu barem jedan od atoma prstena je dušik, kisik ili sumpor, pri čemu heterocikloalkilna skupina ne sadrži atome osim ugljika, vodika, dušika, kisika i sumpora, pri čemu, ako je prisutan više od jednog prstena, prstenovi mogu biti kondenzirani ili nekondenzirani, pri čemu, jedna ili više alkilnih skupina može biti spojena na prsten ili prstenski sustav, ako to dozvoljava ograničenje broja ugljika, te pri čemu jedna ili više dvostrukih veza može biti prisutna u prstenu ili prstenskom sustavu, pod uvjetom da nastala skupina ostaje ne-aromatska;
incubating said partly AX-REED treated liquid in said chamber, whereby the direction of electric field is reversed at intervals, 
VIII. inkubiranje navedene djelomično obrađene tekućine AX-REED u navedenoj komori, pri čemu se smjer električnog polja preokreće u intervalima;
When the pH is lowered thereafter (i.e. 
Kada se nakon toga pH vrijednost snizi (npr.
The computer system of claim 1, wherein the number of levels of address translation tables is based on at least one of a size of an assigned address space that includes the memory address, a size of one or more address translation tables to be used in the converting, and a size of a unit of memory accessed by the memory address. 
Metoda iz patentnog zahtjeva 1, pri čemu je broj razina tablica prevođenja adrese temeljen na barem jednoj od veličina prostora pridruženog adresi koji uključuje memorijsku adresu, veličina jedne ili više tablica prevođenja adrese koristit će se u pretvorbi, a veličina jedinice memorije kojoj je pristupljeno memorijskom adresom.
A method for supplying combustion air in a vertical incinerator in which waste is charged in a sequence into a vertical furnace to combust the waste while the combustion air is supplied to deposit layers that are formed by the waste charged into the furnace, and incineration treatment for the waste is implemented by sequentially discharging incineration ash that results after completion of the combustion from a bottom portion to outside of the furnace, the method comprising: 
Postupak dopreme zraka za izgaranje u okomitom spaljivaču (1), gdje se otpad (R) postupno dodaje u okomitu peć kako bi se sagorio otpad dok se doprema zrak za izgaranje u taložne slojeve koji nastaju iz otpada kojim se puni peć, a obrada otpada spaljivanjem se provodi postupnim ispuštanjem van pepela nastalog spaljivanjem (A) nakon dovršenja izgaranja iz pridnenog dijela peći, otpad sadrži smjesu zapaljivih materijala visoke kalorične vrijednosti s nezapaljivim materijalima, naznačen time što postupak obuhvaća:
The support leg of claim 6, wherein the handle (9) is fashioned in a single body with the drive shaft (8). 
Nosivi krak prema zahtjevu 6, naznačen time, da je ručka (9) načinjena u jednom komadu zajedno s pogonskom osovinom (8).
Purification and Concentration of the Thorium 228 As may be seen in FIG. 
Cc) pročišćavanje i koncentracija torija 228 izdvojenog tim postupkom.
Embodiment 11. The method of any of the foregoing Embodiments, wherein the C8-C11 alkane compound having one branch includes an isomer of decane selected from the group consisting of 2-methylnonane, 3-methylnonane, 4-methylnonane, 5-methylnonane, 3-ethyloctane, 4-ethyloctane, and 4-propylheptane. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što C8-C11 alkanski spoj s jednom granom sadrži izomer dekana kojeg se bira iz skupine koju čine 2-metilnonan, 3-metilnonan, 4-metilnonan, 5-metilnonan, 3-etiloktan, 4-etiloktan, te 4-propilheptan.